针对SARS-CoV-2核体基因的反感性寡核酸降低了仓鼠中的病毒标位
Christopher Fitzpatrick1,2, Nicolas Meunier2, Sophie Lepoder3
1Université Paris-Saclay, AgroParisTech, INRAE, GABI UMR1313, 78350 Jouy-en-Josas, France.
Molecular therapy. Nucleic acids
|July 21, 2025
概括
针对SARS-CoV-2核体RNA的反感性寡核化物 (ASOs) 显示出作为一种新型抗病毒策略的前景. ASO-N1在降低病毒载量和改善受感染仓鼠的临床症状方面表现出显著的有效性.
科学领域:
- 病毒学和分子生物学
- 抗病毒疗法 抗病毒疗法
- 氧核酸治疗药物 治疗药物
背景情况:
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 导致正在进行的COVID-19大流行.
- 新出现的SARS-CoV-2变种和有限的抗病毒疗效需要新的治疗方法.
- 反感性寡核酸 (ASO) 提供了针对病毒RNA的潜在策略.
研究的目的:
- 设计,选和评估针对SARS-CoV-2基因组和亚基因组RNA的反感性寡核酸 (ASO).
- 确定和验证在体内对抗SARS-CoV-2感染的有效性的主要ASO候选者.
- 评估SARS-CoV-2变种中ASO目标部位的保存性.
主要方法:
- 在人类细胞中设计和选针对SARS-CoV-2RNA的ASO,使用基于发光的记者测定和RT-qPCR.
- 在SARS-CoV-2感染的子中进行了体内验证,这些子接受了鼻内和全身ASO-N1的治疗.
- 评估临床症状,病毒RNA水平,细胞因子表达和传染性病毒标位.
- 序列分析以评估跨SARS-CoV-2变种的目标部位保护.
主要成果:
- ASO-N1被选为主要候选者,其向核体RNA.
- 对于仓鼠的ASO-N1治疗显著改善了临床症状,减轻了体重减轻,增加了食物消耗.
- 在鼻腔粘膜中持续减少病毒RNA和炎症性细胞因子,并观察到传染性病毒标位下降.
- 优化ASO-N1化学协同增强了体外抗病毒疗效.
- 在四年内,ASO-N1目标部位在主要的SARS-CoV-2变体中得到保护.
结论:
- 核体RNA向的反感性寡核化物代表了对抗SARS-CoV-2的有希望和强大的抗病毒策略.
- ASO-N1在体内显示出显著的疗效,并有可能对SARS-CoV-2变种具有广泛的适用性.
相关概念视频
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
01:23RNA Interference
26.5K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.5K